Document is current
Any future updates will be listed below
-
Authors
Athauda, Avani
Nankivell, Matthew
Langer, Rupert https://orcid.org/0000-0001-9491-3609
Pritchard, Susan
Langley, Ruth E.
von Loga, Katharina
Starling, Naureen
Chau, Ian https://orcid.org/0000-0003-0286-8703
Cunningham, David https://orcid.org/0000-0001-5158-1069
Grabsch, Heike I. https://orcid.org/0000-0001-9520-6228
-
Funding
Funding for this research was provided by:
Cancer Research UK
- License Information
-
More Information
Article History
Received: 26 July 2022
Revised: 12 December 2022
Accepted: 23 February 2023
First Online: 25 March 2023
Competing interests
: DC: Research funding from MedImmune, AstraZeneca, Clovis, Eli Lily, 4SC, Bayer, Celgene, NIHR EME, and Roche; Scientific advisory board for OVIBIO. IC: Research funding from Eli-Lilly, Janssen-Cilag; Honorarium from Eli-Lilly, Eisai, Servier; Advisory board for Eli-Lilly, Bristol Meyers Squibb, MSD, Roche, Merck-Serono, AstraZeneca, OncXerna, Pierre Fabre, Boehringer Ingelheim, Incyte, Astella, GSK, Sotio, Eisai, Daiichi-Sankyo, Taiho, Servier. Naureen Starling: Research funding from Merck, AstraZeneca, BMS, Pfizer; honoraria from Merck-Serono, Novartis, MSD Oncology, Eli Lily, Pierre Fabre, Amgen, GSK, Servier; Advisory board for Pfizer, Servier, AstraZeneca, MSD Oncology, Novartis; travel funding from AstraZeneca, BMS, Eli Lily, Merck, Roche, MSD Oncology. HIG: Advisory board for AstraZeneca and BMS. The remaining authors declare no competing interests.
: Ethical approval for this study was granted by South West Research Ethics Committee (ref 18/SW/0279). The study was performed in accordance with the Declaration of Helsinki.
: Not applicable.
